Chronic and acute arsenic exposure enhance EGFR expression via distinct molecular mechanisms

Copyright © 2020 Elsevier Ltd. All rights reserved..

The impacts of acute arsenic exposure (i.e. vomiting, diarrhea, and renal failure) are distinct from those brought about by sustained, low level exposure from environmental sources or drinking of contaminated well water. Chronic arsenic exposure is a risk factor for the development of pulmonary diseases, including lung cancer. How arsenic exposure leads to pulmonary disease is not fully understood. Both acute versus chronic arsenic exposure increase EGFR expression, but do so via distinct molecular mechanisms. BEAS-2B cells were exposed to either acute sodium arsenite (5 μM for 24 h) or chronic sodium arsenite (100 nM for 24 weeks). Cells treated with acute arsenic exhibited a decrease in viability, changes in morphology, and increased mRNA level of BTC. In contrast, during 24 weeks of arsenic exposure, the cells had increased EGFR expression and activity, and increased mRNA and protein levels of TGFα. Further, chronic arsenic treatment caused an increase in cell migration in the absence of exogenous ligand. Elevated TGFα and EGFR expression are features of many non-small cell lung cancers. We propose that lung epithelial cells chronically exposed to low level arsenic increases EGFR signaling via TGFα production to enhance ligand-independent cell migration.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:67

Enthalten in:

Toxicology in vitro : an international journal published in association with BIBRA - 67(2020) vom: 01. Sept., Seite 104925

Sprache:

Englisch

Beteiligte Personen:

Kim, Christine [VerfasserIn]
States, J Christopher [VerfasserIn]
Ceresa, Brian P [VerfasserIn]

Links:

Volltext

Themen:

48OVY2OC72
Arsenic
Arsenites
BEAS-2B
EC 2.7.10.1
EGFR
EGFR protein, human
ErbB Receptors
Journal Article
Sodium Compounds
Sodium arsenite
TGFα
Transforming Growth Factor beta

Anmerkungen:

Date Completed 12.03.2021

Date Revised 03.09.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.tiv.2020.104925

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM311773397